BioCentury
ARTICLE | Clinical News

Bextra valdecoxib regulatory update

November 15, 2004 8:00 AM UTC

PFE received a non-approvable letter from the FDA for Bextra, once-daily cyclooxygenase-2 (COX-2) inhibitor, for migraines. Also, PFE reported that they are engaged in talks with FDA to strengthen th...